Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending September 14, 2017. The report details a significant regulatory milestone for GSK's vaccine division regarding the candidate vaccine "Shingrix" (HZ/su), intended for the prevention of herpes zoster (shingles) in adults aged 50 and over.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report of a specific corporate event rather than a periodic financial statement.
Material Changes and Developments
- FDA Advisory Committee Vote: The Vaccines and Related Biological Products Advisory Committee (VRBPAC) of the US FDA voted unanimously that data supports the efficacy and safety of Shingrix for adults 50 and over.
- Regulatory Status: The Biologics License Application (BLA) was submitted in October 2016. While the advisory vote is positive, the final approval decision rests with the FDA. The vaccine is not currently approved for use anywhere in the world.
- Global Filings: Regulatory filings are underway in the European Union, Canada, Australia, and Japan.
Outlook, Risks, and Management Commentary
Dr. Emmanuel Hanon, Senior Vice President and Head of Vaccines R&D, stated that the vote brings the company closer to approval for a vaccine designed to overcome age-related weakening of the immune system. Management highlighted the significant market need, noting that up to one in three people in the US will develop shingles.
Risks and Contingencies: The filing includes a cautionary statement regarding forward-looking statements. Actual results may differ materially due to risks described in the company's 2016 Annual Report on Form 20-F. The advisory committee's recommendation is non-binding, and final FDA approval is not guaranteed.
Investor Verification Checklist
- Confirm the final FDA approval decision following the unanimous advisory committee vote.
- Monitor the status of regulatory filings in the EU, Canada, Australia, and Japan.
- Review the 2016 Annual Report on Form 20-F for detailed risk factors affecting the vaccine portfolio.
- Verify the commercial launch timeline and pricing strategy once regulatory approval is granted.